Tariff-related Litigation Update – 8/15
IEEPA Tariffs & Legal Challenge Update (8/15/2025)
This members-only briefing provides weekly updates on tariff actions and related litigation. It includes developments under Executive Order 14257 (as amended), recent tariff threats—including proposed “fentanyl” tariffs under IEEPA—and ongoing judicial activity in key trade and customs cases. Each update summarizes the latest filings, decisions, or scheduling milestones in active challenges brought by industry stakeholders.
Related Reading
News / Global & Trade / Supply Chain / Tariffs
AdvaMed Responds to Commerce Department Section 232 National Security Investigation, Seeks Policies to Strengthen U.S. Position as Global Medtech Leader
October 17, 2025
WASHINGTON—AdvaMed, the medtech association, today submitted formal comments responding to the U.S. Department of Commerce investigation into whether the U.S.’s current level of medtech imports has national security implications. The comments outlined medtech as an American success story and the United States as the global leader in innovating and making the highest quality medtech for the United States and world, an export powerhouse, and much less reliant on medtech imports than sometimes perceived.
News / Global & Trade / Government & Legislative Affairs / Health Access / Supply Chain / Tariffs
AdvaMed Statement on Commerce Department Section 232 National Security Investigation
September 25, 2025
WASHINGTON—AdvaMed, the MedTech Association, released the following statement from President and CEO Scott Whitaker on the Administration’s announcement of its investigation under Section 232 of the Trade Expansion Act into whether the U.S.’s current level of medtech imports has national security implications:
Resource / Emerging Policy Response Resources / Tariffs
Tariff-related Litigation Update – 9/12
September 12, 2025
Member-only overview of IEEPA reciprocal & “fentanyl” tariffs under EO 14257, summarizing key federal court challenges and rulings through August 15, 2025.
Resource / Emerging Policy Response Resources / Tariffs
Tariff-related Litigation Update – 9/5
September 5, 2025
Member-only overview of IEEPA reciprocal & “fentanyl” tariffs under EO 14257, summarizing key federal court challenges and rulings through August 15, 2025.
Resource / Emerging Policy Response Resources / Tariffs
Tariff-related Litigation Update – 8/22
August 22, 2025
Member-only overview of IEEPA reciprocal & “fentanyl” tariffs under EO 14257, summarizing key federal court challenges and rulings through August 15, 2025.
Resource / Emerging Policy Response Resources / Government & Legislative Affairs / Tariffs
Scott Whitaker Op-Ed: Medtech is vital to a healthier America
August 12, 2025
A powerful op-ed from AdvaMed’s CEO explaining why tariffs could undermine U.S. medtech innovation, jobs, and patient care—and what must be done.
Resource / Emerging Policy Response Resources / Tariffs
Tariff-related Litigation Update – 7/25
July 25, 2025
Member-only overview of IEEPA reciprocal & “fentanyl” tariffs under EO 14257, summarizing key federal court challenges and rulings through July 25, 2025.
Resource / Emerging Policy Response Resources / Tariffs
Tariff-related Litigation Update – 7/18
July 18, 2025
Member-only overview of IEEPA reciprocal & “fentanyl” tariffs under EO 14257, summarizing key federal court challenges and rulings through July 18, 2025.